The recent surge in funding into boutique pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the promise for revolutionary treatments and substantial returns is clear, the linked risks are also significant. Many of these pr… Read More